Literature DB >> 20162434

FY polymorphisms and vivax malaria in inhabitants of Amazonas State, Brazil.

Sérgio Roberto Lopes Albuquerque1, Francimary de Oliveira Cavalcante, Edalton Cesar Sanguino, Lucianna Tezza, Fernanda Chacon, Lilian Castilho, Maria Cristina dos Santos.   

Abstract

Although the importance of glycoprotein Duffy in the human red cells invasion process by Plasmodium vivax merozoites has been demonstrated, little is known about the associations of FY polymorphisms with malaria vivax parasitic density. In this study, we investigated the associations of the SNPs 125 G>A, 265 C>T, and 298 G>A on FY gene and the SNP -33T>C on GATA box with the vivax malaria parasitic density in inhabitants of Amazon State, Brazil. Verifications of P. vivax, as well as the definition of parasitism, were determined by standard screening tests in 497 patients. FY phenotyping was performed in all samples by hemagglutination using gel cards. Molecular analysis for FY/GATA polymorphisms were performed by polymerase chain reaction-restriction fragment length polymorphism. Our data showed that in this population, FY*A/FY*B-33 and FY*B/FY*B-33 genotypes may be a selective advantage, reducing the frequency of P. vivax infection in the studied area. FY*A/FY*B and FY*A/FY*A genotypes showed to be associated with the rise of the frequency of P. vivax infection, and FY*B/FY*X and FY*A/FY*X showed to be associated with the low levels of parasitism. These results suggest that natural adaptations, in malaria-endemic regions, could be leading to the arising of partial defense mechanisms against P. vivax, which is different from the previously described in African descents, as well as adaptations that could be increasing the susceptibility of human to this kind of malaria.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20162434     DOI: 10.1007/s00436-010-1745-x

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  21 in total

1.  Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of the P. vivax ligand required for blood-stage infection.

Authors:  P Michon; I Woolley; E M Wood; W Kastens; P A Zimmerman; J H Adams
Journal:  FEBS Lett       Date:  2001-04-20       Impact factor: 4.124

2.  Competition for red blood cells can enhance Plasmodium vivax parasitemia in mixed-species malaria infections.

Authors:  Philip G McQueen; F Ellis McKenzie
Journal:  Am J Trop Med Hyg       Date:  2006-07       Impact factor: 2.345

3.  Invasion of erythrocytes by malaria merozoites.

Authors:  J A Dvorak; L H Miller; W C Whitehouse; T Shiroishi
Journal:  Science       Date:  1975-02-28       Impact factor: 47.728

4.  Differential expression of the duffy antigen receptor for chemokines according to RBC age and FY genotype.

Authors:  I J Woolley; K A Hotmire; R M Sramkoski; P A Zimmerman; J W Kazura
Journal:  Transfusion       Date:  2000-08       Impact factor: 3.157

Review 5.  Cross-species regulation of Plasmodium parasitemia in semi-immune children from Papua New Guinea.

Authors:  Marian C Bruce; Karen P Day
Journal:  Trends Parasitol       Date:  2003-06

6.  Dynamics of asymptomatic Plasmodium vivax infections and Duffy binding protein polymorphisms in relation to parasitemia levels in Papua New Guinean children.

Authors:  Jennifer L Cole-Tobian; Pascal Michon; Elijah Dabod; Ivo Mueller; Christopher L King
Journal:  Am J Trop Med Hyg       Date:  2007-11       Impact factor: 2.345

7.  Eroding the resistance of Duffy negativity to invasion by Plasmodium vivax?

Authors:  Geoffrey Pasvol
Journal:  Trans R Soc Trop Med Hyg       Date:  2007-07-20       Impact factor: 2.184

8.  A novel mutation in the coding sequence of the FY*B allele of the Duffy chemokine receptor gene is associated with an altered erythrocyte phenotype.

Authors:  N Parasol; M Reid; M Rios; L Castilho; I Harari; N S Kosower
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

9.  Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals.

Authors:  C Tournamille; Y Colin; J P Cartron; C Le Van Kim
Journal:  Nat Genet       Date:  1995-06       Impact factor: 38.330

Review 10.  Duffy blood group and malaria.

Authors:  Dante M Langhi; José Orlando Bordin
Journal:  Hematology       Date:  2006-10       Impact factor: 2.269

View more
  15 in total

1.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.

Authors:  Dorota Smolarek; Claude Hattab; Gholamreza Hassanzadeh-Ghassabeh; Sylvie Cochet; Carlos Gutiérrez; Alexandre G de Brevern; Rachanee Udomsangpetch; Julien Picot; Magdalena Grodecka; Kazimiera Wasniowska; Serge Muyldermans; Yves Colin; Caroline Le Van Kim; Marcin Czerwinski; Olivier Bertrand
Journal:  Cell Mol Life Sci       Date:  2010-05-11       Impact factor: 9.261

Review 2.  Malaria-related anaemia: a Latin American perspective.

Authors:  Juan Pablo Quintero; André Machado Siqueira; Alberto Tobón; Silvia Blair; Alberto Moreno; Myriam Arévalo-Herrera; Marcus Vinícius Guimarães Lacerda; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 3.  Red blood cell polymorphism and susceptibility to Plasmodium vivax.

Authors:  Peter A Zimmerman; Marcelo U Ferreira; Rosalind E Howes; Odile Mercereau-Puijalon
Journal:  Adv Parasitol       Date:  2013       Impact factor: 3.870

Review 4.  Potential immune mechanisms associated with anemia in Plasmodium vivax malaria: a puzzling question.

Authors:  Thiago Castro-Gomes; Luiza C Mourão; Gisely C Melo; Wuelton M Monteiro; Marcus V G Lacerda; Érika M Braga
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

5.  A long neglected world malaria map: Plasmodium vivax endemicity in 2010.

Authors:  Peter W Gething; Iqbal R F Elyazar; Catherine L Moyes; David L Smith; Katherine E Battle; Carlos A Guerra; Anand P Patil; Andrew J Tatem; Rosalind E Howes; Monica F Myers; Dylan B George; Peter Horby; Heiman F L Wertheim; Ric N Price; Ivo Müeller; J Kevin Baird; Simon I Hay
Journal:  PLoS Negl Trop Dis       Date:  2012-09-06

6.  Vivax malaria in Mauritania includes infection of a Duffy-negative individual.

Authors:  Nathalie Wurtz; Khadijetou Mint Lekweiry; Hervé Bogreau; Bruno Pradines; Christophe Rogier; Ali Ould Mohamed Salem Boukhary; Jamal Eddine Hafid; Mohamed Salem Ould Ahmedou Salem; Jean-François Trape; Leonardo K Basco; Sébastien Briolant
Journal:  Malar J       Date:  2011-11-03       Impact factor: 2.979

Review 7.  Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature.

Authors:  Marcus V G Lacerda; Maria P G Mourão; Márcia A A Alexandre; André M Siqueira; Belisa M L Magalhães; Flor E Martinez-Espinosa; Franklin S Santana Filho; Patrícia Brasil; Ana M R S Ventura; Mauro S Tada; Vanja S C D Couto; Antônio R Silva; Rita S U Silva; Maria G C Alecrim
Journal:  Malar J       Date:  2012-01-09       Impact factor: 2.979

8.  Analysis for genotyping Duffy blood group in inhabitants of Sudan, the fourth cataract of the Nile.

Authors:  Agnieszka Kempińska-Podhorodecka; Oktawian Knap; Arleta Drozd; Mariusz Kaczmarczyk; Miroslaw Parafiniuk; Milosz Parczewski; Andrzej Ciechanowicz
Journal:  Malar J       Date:  2012-04-17       Impact factor: 2.979

9.  Investigation of host candidate malaria-associated risk/protective SNPs in a Brazilian Amazonian population.

Authors:  Simone da Silva Santos; Taane G Clark; Susana Campino; Martha Cecília Suarez-Mutis; Kirk A Rockett; Dominic P Kwiatkowski; Octavio Fernandes
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

10.  Plasmodium vivax infection in Anajás, State of Pará: no differential resistance profile among Duffy-negative and Duffy-positive individuals.

Authors:  Tarcisio A A Carvalho; Maíse G Queiroz; Greice L Cardoso; Isabela G Diniz; Aylla N L M Silva; Ana Y N Pinto; João F Guerreiro
Journal:  Malar J       Date:  2012-12-22       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.